Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used
Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used inminimally invasive procedures to treat neurovascular diseases.Target also has a strong position in interventional neuroradiology.
Boston Scientific plans to trade 1.07 shares of its stock foreach Target share in a stock swap valued at $1.1 billion. Targetlast week posted revenues for its third quarter of fiscal 1997(end-December) of $23.9 million, compared with $19 million inthe same period of fiscal 1996. The company had third-quarternet income of $3.8 million, compared with $3.6 million in thesame period a year ago. The acquisition is expected to close inthe second quarter.
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.